FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075333933> ?p ?o ?g. }

• W2075333933 endingPage "1350" @default.
• W2075333933 startingPage "1344" @default.
• W2075333933 abstract "We conducted a phase I/II study to investigate the toxicity, pharmacokinetics, and efficacy profiles of cladribine with 2-h intravenous infusion for five consecutive days every four weeks in Japanese patients with relapsed indolent B-cell lymphoma. This was a dose-escalation study to confirm the safety of the doses which have been recommended for Caucasian patients (phase I), and to further evaluate the efficacy and safety (phase II). In the phase I portion for nine patients, no dose-limiting toxicities were observed at levels 1 (0.09 mg/kg/day, n = 3) and 2 (0.12 mg/kg/day, n = 6). No appreciable accumulation of plasma cladribine concentration was suggested. We enrolled a total of 20 patients, and an additional 14 patients in the phase II portion at level 2 (0.12 mg/kg/day). Eighteen patients, including 13 with follicular lymphoma, were eligible for efficacy evaluation, and 15 (83%) were pretreated with rituximab. The overall response rate was 50% (9/18; 80% confidence interval, 35-65%), with 11% (2/18) complete response. With a median follow-up of 296 days, the estimated median time to progression for 18 eligible patients was 382 days. The most frequent adverse events were hematologic toxicities, including grade 4 neutropenia. Non-hematologic toxicities were mild. In conclusion, cladribine with 2-h intravenous infusion for five consecutive days every four weeks is effective with acceptable toxicities for Japanese patients with relapsed indolent B-cell lymphoma, including those pretreated with rituximab." @default.
• W2075333933 created "2016-06-24" @default.
• W2075333933 creator A5000733045 @default.
• W2075333933 creator A5000985713 @default.
• W2075333933 creator A5002091607 @default.
• W2075333933 creator A5006710981 @default.
• W2075333933 creator A5013490553 @default.
• W2075333933 creator A5015509689 @default.
• W2075333933 creator A5036000764 @default.
• W2075333933 creator A5037105339 @default.
• W2075333933 creator A5053906265 @default.
• W2075333933 creator A5054033361 @default.
• W2075333933 creator A5062359155 @default.
• W2075333933 creator A5072163593 @default.
• W2075333933 creator A5077400696 @default.
• W2075333933 creator A5084751660 @default.
• W2075333933 creator A5087154078 @default.
• W2075333933 creator A5090955736 @default.
• W2075333933 creator A5091074660 @default.
• W2075333933 date "2009-07-01" @default.
• W2075333933 modified "2023-10-01" @default.
• W2075333933 title "Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab" @default.
• W2075333933 cites W121485390 @default.
• W2075333933 cites W1736849829 @default.
• W2075333933 cites W1747828481 @default.
• W2075333933 cites W1792577025 @default.
• W2075333933 cites W1910669649 @default.
• W2075333933 cites W1912693401 @default.
• W2075333933 cites W1937167576 @default.
• W2075333933 cites W1973642808 @default.
• W2075333933 cites W1982880474 @default.
• W2075333933 cites W1988446588 @default.
• W2075333933 cites W1995570857 @default.
• W2075333933 cites W2034861381 @default.
• W2075333933 cites W2039131971 @default.
• W2075333933 cites W2042418843 @default.
• W2075333933 cites W2072199204 @default.
• W2075333933 cites W2076668534 @default.
• W2075333933 cites W2092004631 @default.
• W2075333933 cites W2101141816 @default.
• W2075333933 cites W2103140628 @default.
• W2075333933 cites W2117291755 @default.
• W2075333933 cites W2130969726 @default.
• W2075333933 cites W2132443196 @default.
• W2075333933 cites W2134057518 @default.
• W2075333933 cites W2135321054 @default.
• W2075333933 cites W2138984197 @default.
• W2075333933 cites W2141289246 @default.
• W2075333933 cites W2149420411 @default.
• W2075333933 cites W2152564948 @default.
• W2075333933 cites W2154643481 @default.
• W2075333933 cites W2162903487 @default.
• W2075333933 cites W2229733741 @default.
• W2075333933 cites W2271724340 @default.
• W2075333933 cites W2277092007 @default.
• W2075333933 cites W2292664782 @default.
• W2075333933 cites W2313345753 @default.
• W2075333933 cites W2314659489 @default.
• W2075333933 cites W78071506 @default.
• W2075333933 doi "https://doi.org/10.1111/j.1349-7006.2009.01162.x" @default.
• W2075333933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19432900" @default.
• W2075333933 hasPublicationYear "2009" @default.
• W2075333933 type Work @default.
• W2075333933 sameAs 2075333933 @default.
• W2075333933 citedByCount "7" @default.
• W2075333933 countsByYear W20753339332013 @default.
• W2075333933 countsByYear W20753339332018 @default.
• W2075333933 countsByYear W20753339332020 @default.
• W2075333933 crossrefType "journal-article" @default.
• W2075333933 hasAuthorship W2075333933A5000733045 @default.
• W2075333933 hasAuthorship W2075333933A5000985713 @default.
• W2075333933 hasAuthorship W2075333933A5002091607 @default.
• W2075333933 hasAuthorship W2075333933A5006710981 @default.
• W2075333933 hasAuthorship W2075333933A5013490553 @default.
• W2075333933 hasAuthorship W2075333933A5015509689 @default.
• W2075333933 hasAuthorship W2075333933A5036000764 @default.
• W2075333933 hasAuthorship W2075333933A5037105339 @default.
• W2075333933 hasAuthorship W2075333933A5053906265 @default.
• W2075333933 hasAuthorship W2075333933A5054033361 @default.
• W2075333933 hasAuthorship W2075333933A5062359155 @default.
• W2075333933 hasAuthorship W2075333933A5072163593 @default.
• W2075333933 hasAuthorship W2075333933A5077400696 @default.
• W2075333933 hasAuthorship W2075333933A5084751660 @default.
• W2075333933 hasAuthorship W2075333933A5087154078 @default.
• W2075333933 hasAuthorship W2075333933A5090955736 @default.
• W2075333933 hasAuthorship W2075333933A5091074660 @default.
• W2075333933 hasConcept C112705442 @default.
• W2075333933 hasConcept C126322002 @default.
• W2075333933 hasConcept C197934379 @default.
• W2075333933 hasConcept C2777058707 @default.
• W2075333933 hasConcept C2777063308 @default.
• W2075333933 hasConcept C2779200787 @default.
• W2075333933 hasConcept C2779338263 @default.
• W2075333933 hasConcept C2780653079 @default.
• W2075333933 hasConcept C29730261 @default.
• W2075333933 hasConcept C31760486 @default.
• W2075333933 hasConcept C71924100 @default.
• W2075333933 hasConcept C90924648 @default.

• next